戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  Interferons (IFNs) and retinoids are potent biological response modifiers.
2 ased therapies, including growth factors and biological response modifiers.
3 une-modulatory agents, cytostatic drugs, and biological response modifiers.
4 uct with either leukocyte allo-antibodies or biological response modifiers.
5 eening of anticancer therapeutics, including biological response modifiers.
6  the xenotransplantation subcommittee of the Biological Response Modifiers Advisory Committee to disc
7 onundrum, and recent prospective trials with biological response modifiers aimed at the inflammatory
8 scular beds, as well as through secretion of biological response modifiers and recruitment of immune
9 rotein member of the TGF-beta superfamily of biological-response modifiers, causes regression of the
10                                              Biological response modifiers, cytoprotective drugs, sal
11  to be caused by antileukocyte antibodies or biological response modifiers (eg, lipids).
12 nctional Assessment of Cancer Therapy (FACT) Biological Response Modifiers (FACT-BRM), FACT-General,
13                                PDT acts as a biological response modifier in addition to directly dam
14  increase in immunogenicity provided by this biological response modifier in an otherwise well-tolera
15         Ingested interferon (IFN)-alpha is a biological response modifier in experimental autoimmune
16 omodulatory properties and can function as a biological response modifier in vivo.
17   Issues concerning the safety of the use of biological response modifiers in inducing sarcoidosis ne
18 syl-(1-3)-beta-glucopyranose (PGG) glucan, a biological-response modifier, in protecting against mort
19                            This new class of biological response modifiers may be applicable to the c
20                    Moreover, the nonspecific biological response modifier monophosphoryl lipid A (MPL
21          However, a combination of these two biological response modifiers significantly suppressed t
22      Interleukin-7 (IL-7) is a proteinaceous biological response modifier that has a bioactive tertia
23 ulation, indicating that Thy-1 is a critical biological response modifier that protects against fibro
24         Moreover, pharmacological agents and biological response modifiers that independently display
25          Mounting evidence suggests that the biological response modifiers, which consistently produc
26 RA) represent a growing class of pleiotropic biological response modifiers with demonstrable efficacy